Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).

Abstract: 2517 | Poster Bd #: 359: Frederick Locke, Lazaros Lekakis, Herbert Eradat, et al.

Presenter: Frederick L. Locke MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.

Abstract: 2518 | Poster Bd #: 360: Andreas Mackensen, John Haanen, Christian Koenecke, et al.

Presenter: Andreas Mackensen, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.

Abstract: 2519 | Poster Bd #: 361: Benjamin Schlechter, Daniel Olson, Mridula George, et al.

Presenter: Benjamin L. Schlechter, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors.

Abstract: 2520 | Poster Bd #: 362: Dongmei Ji, Yao Weitao, Xiangmin Tong, et al.

Presenter: Dongmei Ji MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).

Abstract: 2521 | Poster Bd #: 363:Kamaneh Montazeri, Diwakar Davar, Cara Haymaker, et al.

Presenter: Kamaneh Montazeri MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

The immune microenvironment in hormone positive, HER2 negative breast cancer: A focus on tumour infiltrating lymphocytes, spatial phenotypes and tertiary lymphoid structures.

Abstract: 2522 | Poster Bd #: 364: Mairi Lucas, Zak Kinsella, Claudia Gonzalez, et al.

Presenter: Mairi Lucas MBChB

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).

Abstract: 2523 | Poster Bd #: 365: Ira Winer, Amita Patnaik, Minal Barve, et al.

Presenter: Ira Seth Winer MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.

Abstract: 2524 | Poster Bd #: 366: Minal Barve, Anthony Tolcher, Richard Carvajal, et al.

Presenter: Minal A. Barve MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.

Abstract: 2525 | Poster Bd #: 367: Adil Daud, Costantine Albany, Vamsidhar Velcheti, et al.

Presenter: Adil Daud

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.

Abstract: 2526 | Poster Bd #: 368: Pei Shu, Xiaoyu Li, Li Yuan, Qi Zhou, et al.

Presenter: Pei Shu

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.

Abstract: 2527 | Poster Bd #: 369: Matthew Koshy, Michael Spiotto, Lawrence Feldman, et al.

Presenter: Matthew Koshy MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.

Abstract: 2528 | Poster Bd #: 370: Eileen O'Reilly, Zev Wainberg, Colin Weekes, et al.

Presenter: Eileen Mary O'Reilly, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session, you need an ASCO Annual Meeting registration.

Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study.

Abstract: 2512 :

Presenter: Delvys Rodriguez-Abreu, MD, PhD

----------------------------------------------------------------------------------------------------------------------

Targeting CD47 in lymphoid malignancies with CAR T cells.

Abstract: 2513 :

Presenter:Alexander Paul Boardman

----------------------------------------------------------------------------------------------------------------------

Association of common inherited NOD2 mutations with exceptional response to immune checkpoint inhibitors.

Abstract: 2514 :

Presenter: Megan Babette Barnet, PhD, BS, MBBS, FRACP

----------------------------------------------------------------------------------------------------------------------

Intestinal microbiome characterization in immune checkpoint inhibition (ICI) resistant disease.

Abstract: 2515 :

Presenter: Pavlina Spiliopoulou, MD, PhD

----------------------------------------------------------------------------------------------------------------------

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.

Abstract: 2516:

Presenter: Filippo Gustavo Dall’Olio MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Rapid Abstract Session, you need an ASCO Annual Meeting registration.

Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.

Abstract: 2509:

Presenter: Karina Ruiz-Esteves

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-line treatment of fecal microbiota transplantation for immune-mediated colitis.

Abstract: 2510:

Presenter: Yinghong Wang

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Identifying molecular targets for rational immunosuppressive strategies in patients with immune checkpoint therapy-induced myocarditis and myositis.

Abstract: 2511:

Presenter: Bilal Ahmed Siddiqui MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Clinical Science Symposium, you need an ASCO Annual Meeting registration.

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

Abstract: LBA10:

Presenter: Heather A. Wakelee, MD, FASCO

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.

Abstract: 10:

Presenter: Irene L.M. Reijers MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).

Abstract: 10:

Presenter: Denise Wolf

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).

Abstract: 103:

Presenter: Lisa Derosa MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Clinical Science Symposium, you need an ASCO Annual Meeting registration.

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.

Abstract: 3009 | Poster Bd #: 207: Timothy Yap, Antonio Giordano, Erika Hamilton, et al.

Presenter: Timothy A. Yap MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

Abstract: 3010 | Poster Bd #: 208: Timothy Yap, Abdelaziz Elhaddad, Rachel Grisham, et al.

Presenter: Timothy A. Yap MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.

Abstract: 3011 | Poster Bd #: 209: Shao Zhimin, Lei Fan, Ma Linxiaoxi, et al.

Presenter: Shao Zhimin, MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.

Abstract: 3012 | Poster Bd #: 210: Hans Gelderblom, Mathilde Jalving, Ingrid Desar, et al.

Presenter: Hans Gelderblom MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).

Abstract: 3014 | Poster Bd #: 212: Hiroya Taniguchi, Masataka Yagisawa, Taroh Satoh, et al.

Presenter: Hiroya Taniguchi, MD, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.

Abstract: 3015 | Poster Bd #: 213: Manish Sharma, Yasutoshi Kuboki, D. Camidge, et al.

Presenter: Manish Sharma MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.

Abstract: 3016 | Poster Bd #: 214: Yakun Wang, Jifang Gong, Rongbo Lin, et al.

Presenter: Yakun Wang, PhD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Abstract: 3017 | Poster Bd #: 215: Jie Wang, Jianchun Duan, Ligang Xing, et al.

Presenter: Jianchun Duan

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.

Abstract: 3018 | Poster Bd #: 216: Apostolia Tsimberidou, David Vining, Sukeshi Arora, et al.

Presenter: Apostolia Maria Tsimberidou MD, PhD, FASCO

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.

Abstract: 3019 | Poster Bd #: 217: Sarina Piha-Paul, Sanjay Goel, Chih-Yi Liao, et al.

Presenter: Milind M. Javle MD

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.

Abstract: 3020 | Poster Bd #: 218: Alexander Drilon, Melissa Johnson, Shirish Gadgeel, et al.

Presenter: Alexander E. Drilon

Zusammenfassung folgt

----------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Poster Discussion Session, you need an ASCO Annual Meeting registration.